disulfiram has been researched along with Local Neoplasm Recurrence in 9 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Preclinical studies have suggested promising activity for the combination of disulfiram and copper (DSF/Cu) against glioblastoma (GBM) including re-sensitization to temozolomide (TMZ)." | 9.30 | A multicenter phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma. ( Boockvar, J; Campian, JL; Chaudhary, R; Chinnaiyan, P; Cohen, AL; Fink, K; Goldlust, S; Huang, J; Marcus, S; Wan, L, 2019) |
| "Preclinical studies have suggested promising activity for the combination of disulfiram and copper (DSF/Cu) against glioblastoma (GBM) including re-sensitization to temozolomide (TMZ)." | 5.30 | A multicenter phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma. ( Boockvar, J; Campian, JL; Chaudhary, R; Chinnaiyan, P; Cohen, AL; Fink, K; Goldlust, S; Huang, J; Marcus, S; Wan, L, 2019) |
| "Disulfiram was poorly tolerated with six patients experiencing grade 3 adverse events (three per cohort)." | 2.78 | Pharmacodynamic study of disulfiram in men with non-metastatic recurrent prostate cancer. ( Armstrong, AJ; Bardia, A; Blackford, A; Carducci, MA; King, S; Lin, J; Rudek, MA; Schweizer, MT; Yegnasubramanian, S, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (11.11) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 5 (55.56) | 24.3611 |
| 2020's | 2 (22.22) | 2.80 |
| Authors | Studies |
|---|---|
| Chroma, K | 1 |
| Skrott, Z | 1 |
| Gursky, J | 1 |
| Bacovsky, J | 1 |
| Moudry, P | 1 |
| Buchtova, T | 1 |
| Mistrik, M | 1 |
| Bartek, J | 1 |
| Weiser Drozdkova, D | 1 |
| Smesny Trtkova, K | 1 |
| Huang, J | 1 |
| Chaudhary, R | 1 |
| Cohen, AL | 1 |
| Fink, K | 1 |
| Goldlust, S | 1 |
| Boockvar, J | 1 |
| Chinnaiyan, P | 1 |
| Wan, L | 1 |
| Marcus, S | 1 |
| Campian, JL | 1 |
| Kast, RE | 3 |
| Boockvar, JA | 1 |
| Brüning, A | 1 |
| Cappello, F | 1 |
| Chang, WW | 1 |
| Cvek, B | 1 |
| Dou, QP | 1 |
| Duenas-Gonzalez, A | 1 |
| Efferth, T | 1 |
| Focosi, D | 1 |
| Ghaffari, SH | 1 |
| Karpel-Massler, G | 2 |
| Ketola, K | 1 |
| Khoshnevisan, A | 1 |
| Keizman, D | 1 |
| Magné, N | 1 |
| Marosi, C | 1 |
| McDonald, K | 1 |
| Muñoz, M | 1 |
| Paranjpe, A | 1 |
| Pourgholami, MH | 1 |
| Sardi, I | 1 |
| Sella, A | 1 |
| Srivenugopal, KS | 1 |
| Tuccori, M | 1 |
| Wang, W | 1 |
| Wirtz, CR | 1 |
| Halatsch, ME | 2 |
| Schweizer, MT | 1 |
| Lin, J | 1 |
| Blackford, A | 1 |
| Bardia, A | 1 |
| King, S | 1 |
| Armstrong, AJ | 1 |
| Rudek, MA | 1 |
| Yegnasubramanian, S | 1 |
| Carducci, MA | 1 |
| Liu, X | 1 |
| Wang, L | 1 |
| Cui, W | 1 |
| Yuan, X | 1 |
| Lin, L | 1 |
| Cao, Q | 1 |
| Wang, N | 1 |
| Li, Y | 1 |
| Guo, W | 1 |
| Zhang, X | 1 |
| Wu, C | 1 |
| Yang, J | 1 |
| Belda-Iniesta, C | 1 |
| Griffin, AC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II, Multicenter, Open-Label, Single-Arm Study to Evaluate the Safety, Tolerability, and Efficacy of DIsulfiram and Copper Gluconate in Recurrent Glioblastoma[NCT03034135] | Phase 2 | 23 participants (Actual) | Interventional | 2017-03-09 | Completed | ||
| Phase II Open Labeled Trial of Disulfiram With Copper in Metastatic Breast Cancer[NCT03323346] | Phase 2 | 150 participants (Anticipated) | Interventional | 2017-09-29 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Duration of overall survival for patients that are alive (NCT03034135)
Timeframe: 14 months
| Intervention | months (Median) |
|---|---|
| DSF-Cu | 7.1 |
Duration of progression free survival according to RANO criteria (NCT03034135)
Timeframe: 12 months
| Intervention | months (Median) |
|---|---|
| DSF-Cu | 1.7 |
Number of Participants with Grade 3 and 4 serious adverse events (NCT03034135)
Timeframe: 14 months
| Intervention | Participants (Count of Participants) |
|---|---|
| DSF-Cu | 2 |
Percentage of patients that are free from progressive disease per RANO criteria (NCT03034135)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| DSF-Cu | 14 |
ORR will be defined as the percentage of patients with complete response (CR) or partial response (PR) according to the RANO criteria. (NCT03034135)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Complete response | Partial Response | |
| DSF-Cu | 0 | 0 |
Percentage of patients that are alive (NCT03034135)
Timeframe: 6 months and 12 months
| Intervention | percentage of participants (Number) | |
|---|---|---|
| 6 months | 12 months | |
| DSF-Cu | 61 | 35 |
3 reviews available for disulfiram and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Possible Therapeutic Potential of Disulfiram for Multiple Myeloma.
Topics: Cell Line, Tumor; Copper; Disulfiram; Humans; Multiple Myeloma; Neoplasm Recurrence, Local | 2021 |
A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Artemisinins; Auranofin; Brain Neoplasms | 2013 |
Cancer chemoprevention.
Topics: Animals; Antioxidants; Butylated Hydroxytoluene; Carcinogens; Disulfiram; Drug Therapy; Female; Huma | 1980 |
2 trials available for disulfiram and Local Neoplasm Recurrence
| Article | Year |
|---|---|
A multicenter phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma.
Topics: Acetaldehyde Dehydrogenase Inhibitors; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplasti | 2019 |
Pharmacodynamic study of disulfiram in men with non-metastatic recurrent prostate cancer.
Topics: Aged; Antineoplastic Agents; Ceruloplasmin; Disulfiram; DNA Methylation; Epigenesis, Genetic; Humans | 2013 |
4 other studies available for disulfiram and Local Neoplasm Recurrence
| Article | Year |
|---|---|
A drug repurposing strategy for overcoming human multiple myeloma resistance to standard-of-care treatment.
Topics: Antineoplastic Agents; Bortezomib; Cell Line, Tumor; Disulfiram; Drug Repositioning; Drug Resistance | 2022 |
CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Artemisinins; Artesunate; Auran | 2014 |
Targeting ALDH1A1 by disulfiram/copper complex inhibits non-small cell lung cancer recurrence driven by ALDH-positive cancer stem cells.
Topics: Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Animals; Carcinoma, Non-Small-Cell Lung; Ce | 2016 |
Suppressing glioblastoma stem cell function by aldehyde dehydrogenase inhibition with chloramphenicol or disulfiram as a new treatment adjunct: an hypothesis.
Topics: Aldehyde Dehydrogenase; Animals; Brain Neoplasms; Cell Differentiation; Cell Division; Chemotherapy, | 2009 |